References
- Alimohammadian MH, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, Ajdary S, and Kharazmi A (2002) Adjuvant Effect of Leishmania major promastigotes on the immune response of mice to ovalbumin. Iranian Biomed J 6: 123-128
- Arruda MS, Richini VB, Oliveira SM, Vilani-Moreno FR (2004) Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in Thalidomide-treated mice. Braz J Med Biol Res 37: 485-492 https://doi.org/10.1590/S0100-879X2004000400005
- Chatelain R, Mauze S, Coffman RL (1999) Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol 21: 211-218 https://doi.org/10.1046/j.1365-3024.1999.00224.x
- Elso C, Kumar B, Smyth G, Foote S, Handman E (2004) Dissociation of disease susceptibility, inflammation and cytokine profile in lmr1/2 congenic mice infected with Leishmania major. Genes Immun 5: 188-196 https://doi.org/10.1038/sj.gene.6364056
- Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363: 1802-1811 https://doi.org/10.1016/S0140-6736(04)16308-3
- Fu LM, Fu-Liu CS (2002) Thalidomide and tuberculosis. Int J Tuberc Lung Dis 6: 569-572
- Hailu A, van der Poll T, Berhe N, Kager PA (2004) Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71: 561-567
- Handman E (2001) Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev 14: 229-243 https://doi.org/10.1128/CMR.14.2.229-243.2001
- Karrow NA, Guoa TL, Zhanga LX, McCay JA, Musgrovea DL, Peacheea VL, Germolecb DR, White KL Jr (2003) Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study. Int Immunopharmacol 3: 1447-1456 https://doi.org/10.1016/S1567-5769(03)00143-7
- Karrow NA, McCay JA, Brown RD, Musgrove DL, Pettit DA, Munson AE, Germolec DR, White KL Jr (2000) Thalidomide stimulates splenic antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice. Toxicol Appl Pharmacol 165: 237-244 https://doi.org/10.1006/taap.2000.8939
- Lang T, Courret N, Colle JH, Milon G, Antoine JC (2003) The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB / c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum. Infect Immun 71: 2674-2683 https://doi.org/10.1128/IAI.71.5.2674-2683.2003
- Marriott JB, Muller G, Dalgleish AG (1999) Thalidomide as an emerging immuno-therapeutic agent. Immunol Today 20: 538-540 https://doi.org/10.1016/S0167-5699(99)01531-5
- Murray HW (2000) Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 4: 158-177 https://doi.org/10.1016/S1201-9712(00)90078-X
- Murray HW (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45: 2185-2197 https://doi.org/10.1128/AAC.45.8.2185-2197.2001
- Murray HW, Delph-Etienne S (2000) Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 68: 288-293 https://doi.org/10.1128/IAI.68.1.288-293.2000
- Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW (2000) Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 68: 6289-6293 https://doi.org/10.1128/IAI.68.11.6289-6293.2000
- Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 5152-5158 https://doi.org/10.4049/jimmunol.170.10.5152
- Passos VM, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Lima e Costa MF (2000) American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull World Health Organ 78: 968-974
- Sommer F, Meixner M, Mannherz M, Ogilvie AL, Rollinghoff M, Lohoff M (1998) Analysis of cytokine patterns produced by individual CD4+ lymph node cells during experimental murine leishmaniasis in resistant and susceptible mice. Int Immunol 10: 1853-1861 https://doi.org/10.1093/intimm/10.12.1853
- Stenger S, Donhauser N, Thuring H, Rollinghoff M, Bogdan C (1996) Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 183: 1501-1514 https://doi.org/10.1084/jem.183.4.1501
- Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW (1997) Response to interferon-gamma plus antimony in Indian visceral leishmaniasis. J Infect Dis 176: 1117-1119 https://doi.org/10.1086/516526
- Sundar S, Murray HW (1995) Effect of treatment with interferon-gamma alone in Indian visceral leishmaniasis. J Infect Dis 172: 1627-1629 https://doi.org/10.1093/infdis/172.6.1627
- Toledo VP, Mayrink W, Gollob KJ, Oliveira MA, Costa CA, Genaro O, Pinto JA, Afonso LC (2001) Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 96: 89-98 https://doi.org/10.1590/S0074-02762001000100010